Abstract
Pathological histology is the clinical gold standard for cancer diagnosis. Incomplete or excessive sampling of the formalin-fixed excised cancer specimen will result in inaccurate histology assessment or excessive workload. Conventionally, pathologists perform specimen sampling relying on naked-eye observation which is subjective and limited by human perception. Precise identification of tumor beds, size, and margin is challenging, especially for lesions with inconspicuous tumor beds. To break the limits of human eye perception (visible: 400-700 nm) and improve the sampling efficiency, in this study, we propose using a second near-infrared window (NIR-II: 900-1700 nm) hyperspectral imaging (HSI) system to assist specimen sampling on the strength of the verified deep anatomical penetration and low scattering characteristics of the NIR-II optical window. We use selected NIR-II HSI narrow bands to synthesize color images for human eye observation and also apply artificial intelligence (AI)-based algorithm on the complete NIR-II HSI data for automatic tissue classification to assist doctors in specimen sampling. Our study employing 5 pathologists, 92 samples and 7 cancer types shows that NIR-II HSI-assisted methods have significant improvements in determining tumor beds compared with conventional methods (Conventional color image with or without X-ray). The proposed system can be easily integrated into the current workflow, and has high imaging efficiency and no ionizing radiation. It may also find applications in intraoperative detection of residual lesions and identification of different tissues.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the Beijing Fine Inspection Foundation, (Grant No. JJIS2021-011). This study is also supported by Tencent AI Lab, the Fourth Hospital of Hebei Medical University and the West China Hospital, Sichuan University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Fourth Hospital of Hebei Medical University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.